# A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

Source: https://onco.cc/trials/nct07049055/  
OnCo record `nct07049055` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of E-EDV-D682, Gemcitabine, Paclitaxel / nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Engeneic Pty Limited, now recruiting.

## Summary

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer is a phase 1/2 interventional study registered as NCT07049055 by Engeneic Pty Limited, with 144 participants planned, started 2026-01-12 and due to reach its primary completion in 2028-09. Interventions recorded: E-EDV-D682, EDV-GC, Gemcitabine, Nab paclitaxel.. Conditions listed: Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07049055
- Phase: 1/2
- Setting: A Phase I/IIa Randomized Clinical Trial to Evaluate the Efficacy of EGFR-targeted, PNU-159682-packaged Nanocells & Glycolipid-Packaged Nanocells in Combination With Gemcitabine & Nab-paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma
- Sponsor: Engeneic Pty Limited
- Enrolled: 144

## Sources

- ClinicalTrials.gov NCT07049055: https://clinicaltrials.gov/study/NCT07049055

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [E-EDV-D682](https://onco.cc/drugs/e-edv-d682/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)

---
JSON: https://onco.cc/api/v1/entities/nct07049055.json